Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | MMP12 | P39900 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16118629 | 0.84 | KDM4E (0.37) | EPHX2EPHX1KDM4ECA2PTGS1 | |
| SCHEMBL11224012 | 0.84 | KDM4E (0.37) | EPHX2EPHX1KDM4ECA2PTGS1 | |
| SCHEMBL31637667 | 0.78 | EPHX1 (0.31) | EPHX2EPHX1 | |
| SCHEMBL17582410 | 0.77 | EPHX2 (0.39) | EPHX2 | |
| SCHEMBL16118626 | 0.77 | GAA (0.44) | EPHX2EPHX1KDM4ECA2PTGS1 | |
| SCHEMBL24939427 | 0.75 | EPHX2 (0.38) | EPHX2 | |
| SCHEMBL16118630 | 0.75 | EPHX1 (0.31) | EPHX1KDM4ECA2PTGS1MMP12 | |
| SCHEMBL20475966 | 0.75 | EPHX1 (0.31) | EPHX1KDM4ECA2PTGS1MMP12 | |
| SCHEMBL17780263 | 0.75 | EPHX1 (0.31) | EPHX1KDM4ECA2PTGS1MMP12 | |
| SCHEMBL4973914 | 0.75 | GAA (0.47) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250206738-A1 | WRN INHIBITORS | NIMBUS DISCOVERY, INC. | 2025-06-26 | — | — | US | disclosed |
| WO-2025137599-A1 | WRN INHIBITORS | NIMBUS WADJET, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20250129069-A1 | TRIAZOLO WRN INHIBITORS | NIMBUS WADJET, INC. | 2025-04-24 | — | — | US | disclosed |
| US-11708348-B2 | Protease inhibitors for treatment of coronavirus infections | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206738-A1 | WRN INHIBITORS | WRN, BLM, RECQL | EPHX2 3878/4885EPHX1 3460/4885KDM4E 3350/4885 |
| US-20250129069-A1 | TRIAZOLO WRN INHIBITORS | WRN, BLM, RECQL | EPHX2 3862/4885EPHX1 3625/4885KDM4E 3188/4885 |
| US-11708348-B2 | Protease inhibitors for treatment of coronavirus infections | ACE, ACE2, TMPRSS2 | EPHX2 2636/4885EPHX1 1651/4885KDM4E 3429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.